Dare Bioscience Inc (DARE) Peer Comparison

$0.74

$0.00 (0.50%)

As on 28-Aug-2026 10:36EDT

Market cap

$16 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

29.4

Div. Yield

0 %

Edit

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	16	17,326	16,614	13,400	12,305
Revenue ($ Mln)	1	2,782	1,054	2,436	670
Net Profit ($ Mln)	-10.99	491.50	755.85	860.62	-319.95
Net Margin (%)	-804.37	17.67	71.69	35.33	-47.79
RoE (%)	--	110.09	--	42.98	-71.14
Price to Earnings	--	36.49	19.38	17.01	--
Price-To-Book	29.40	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	1.37	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	2.59	1,982.07	103.47	85.67	19.14
Gross Profit	-1.42	760.62	588.53	2,236.43	829.45
Operating Expenses	9.89	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-11.11	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-10.99	598.92	101.11	1,035.47	-252.08
Provision for Tax	0.00	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-10.99	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	-0.56	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	6.01	187.89	384.48	288.55	1,362.63
Current Liabilities	16.92	1,435.43	464.70	361.93	283.35
Total Liabilities	32.47	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	5.68	1,006.90	895.24	1,243.41	440.60
Current Assets	16.69	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	32.47	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	6.76	120.10	449.89	165.93	864.07
Net Current Assets	0.00	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-9.89	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	-0.39	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	19.28	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-3,394.00	53.56	-30.01	32.82	-0.17
ROE (%)	845.53	110.09	163.18	42.98	-71.14
ROA (%)	-30.84	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-571.40	21.13	5.73	31.04	-0.77
Net Margin (%)	-804.37	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	7,816.73	24.67	114.85	9.23	12.22
EBIT Growth (%)	57.43	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	40.94	17.50	378.76	42.89	-115.58
EPS Growth (%)	63.49	26.84	353.27	50.42	-73.87
Book Value Growth (%)	97.38	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-2.09	36.06	-59.76	15.79	-2,869.63
Price / Book Value	9.84	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.57	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	-1.35	0.00	0.05	0.00	0.09
Current Ratio	0.99	0.73	2.99	3.46	5.90
Quick Ratio	0.99	0.73	2.32	3.38	5.90
Interest Coverage	-16.73	--	1.62	--	-1.72

Operating Efficiency Ratios

	Dare Bioscience Inc (DARE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	4.13	15.88	21.25	13.74	1.28
Asset Turnover	0.04	0.89	0.37	0.83	0.34
Receivable days	142.36	50.42	85.52	43.48	1.50
Inventory Days	--	--	1,056.70	96.17	--
Payable days	198.25	6.26	331.01	147.97	221.81
Cash Conversion Cycle	--	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly